Gairin Dancey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gairin Dancey has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Gonzalez-Beltran
Oxford e-Research Centre, Department of Engineering Science, University of Oxford, Oxford, UK
1 shared publication - May Yong
Alan Turing Institute, London, UK
1 shared publication - Richard Begent
UCL Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK
1 shared publication
Latest Publications
- Open Access
- 6 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 10
Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy
Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.
- 6 January 2012
- Published by Springer Nature in BMC Research Notes
- Vol. 5 (1) , 10
Open AccessGuidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy
Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.